Results 101 to 110 of about 23,059 (205)

Expectations and Motivations for Participation in Clinical Trials Utilizing Psychedelics for Treatment‐Resistant Depression: A Qualitative Study

Brain and Behavior, Volume 16, Issue 6, June 2026.
Individuals with treatment‐resistant depression considering psychedelic trial participation were motivated by chronic illness, failed treatments, and hope for a novel intervention, while actively minimizing expectations to guard against disappointment.
Christopher Poppe, Liisa Lyck, Laura Bechtold, Dimitris Repantis   +3 more
wiley   +1 more source

Beyond the numbers: reimagining healing with psychedelics for eating disorders

Journal of Eating Disorders
Psychedelic medicine is currently being evaluated for numerous mental health indications, and there is significant interest in applying these models of care to eating disorders (EDs) given the limited efficacy of available treatment models, especially ...
Adele Lafrance, Meg J. Spriggs, Natalie Gukasyan, Stephanie Knatz Peck   +3 more
doaj   +1 more source

A clinical protocol for group-based ketamine-assisted therapy in a community of practice: the Roots To Thrive model

Frontiers in Psychiatry
BackgroundKetamine-assisted therapy (KaT) has demonstrated therapeutic potential in treating depression, anxiety, and PTSD, driving interest in group-based models of care.
Shannon Dames, Shannon Dames, Pamela Kryskow, Pamela Kryskow, Vivian W. L. Tsang, Elena Argento   +5 more
doaj   +1 more source

Energy‐Based Phase‐Locking State Analysis in Brain State Identification

Human Brain Mapping, Volume 47, Issue 8, June 1, 2026.
EPLSA constructs an energy landscape from BOLD phase synchrony, achieving superior brain state classification and providing novel stability metrics. It demonstrates strong clinical translatability in characterizing sleep–wake transitions and Alzheimer's disease.
Chenfei Ye, Ziyan Deng, Shiqing Cong, Chen Ran, Tao Gong, Shoulin Huang, Ting Ma   +6 more
wiley   +1 more source

Psychedelic Assisted Therapy

This paper aims to identify the effects of ayahuasca on humans and more specifically how this substance defines changes within psychological and behavioral patterns, including experience of emotions, decision-making processes, and life changes. The demand for the new-wave of antidepressants based on psychedelic substances places emphasis on the study ...
openaire   +1 more source

Demoralization and Associated Factors in Palliative Oncology Outpatients: A Cross‐Sectional Study

Psycho-Oncology, Volume 35, Issue 6, June 2026.
ABSTRACT Background Demoralization is common in palliative psycho‐oncology settings. Although its relationship with other psycho‐existential conditions has been scrutinized, its co‐occurrence with adjustment disorder, as measured by the Adjustment Disorder New Module‐20 (ADNM‐20), remains unexamined.
Michael Ljuslin, Vasileios Chytas, Marie‐Estelle Gaignard, Daniel Gorman, Kate Lally, Emanuele Mazzola, Kabir Nigam, Sholevar Roxanne, Zachary Sager, Miryam Yusufov, Sophie Pautex, James Aaron Tulsky, Yvan Beaussant   +12 more
wiley   +1 more source

Provider Perceptions on the Usage of Psychedelic-Assisted Therapy to Influence Behavior Change in Individuals with Substance Use Disorders

, 2023
Recent research studies and clinical trials have suggested that psychedelic therapy with psychological support can offer beneficial and synergistic effects in reducing or eliminating substance use disorder (SUD) patterns and symptoms.
Rausch, Leia T
core  

Psychedelic-Assisted Therapy for Anorexia Nervosa

Journal of Student Research
Anorexia Nervosa is a severe psychiatric disorder characterized by a distorted body image and an intense fear of weight gain, leading to self-imposed caloric restriction and excessive weight loss. Current treatments, including nutritional rehabilitation, psychotherapy, and pharmacological interventions, exhibit low long-term recovery rates. Psychedelic-
Olga Stefańska, Maksymilian Matuszewski
openaire   +1 more source

Rare but relevant: Ibogaine and cardiovascular complications—prolonged QT interval and ventricular arrhythmias

Addiction, Volume 121, Issue 6, Page 1616-1621, June 2026.
Abstract Revived interest in psychedelic‐assisted therapies has also renewed focus on ibogaine, a psychoactive alkaloid, for its notable anti‐addictive potential. Evidence from observational, open‐label, and limited randomized placebo‐controlled trials indicates that ibogaine and its metabolite noribogaine reduce craving and withdrawal symptoms in ...
Tibor Markus Brunt
wiley   +1 more source

Digital Enablement of Psychedelic-Assisted Therapy in Non-Clinical Settings: A Systematic Review of Safety, Efficacy, and Implementation Models

Psychoactives
Psychedelic-assisted therapy offers rapid and profound benefits for treatment-resistant psychiatric conditions but remains constrained by the need for intensive, clinic-based administration.
Brendan Driscoll, Shaheen E. Lakhan
doaj   +1 more source